Your browser doesn't support javascript.
loading
Final 10-year results of the Breast International Group 2-98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer.
Sonnenblick, Amir; Francis, Prudence A; Azim, Hatem A; de Azambuja, Evandro; Nordenskjöld, Bo; Gutiérez, Jorge; Quinaux, Emmanuel; Mastropasqua, Mauro G; Ameye, Lieveke; Anderson, Michael; Lluch, Ana; Gnant, Michael; Goldhirsch, Aron; Di Leo, Angelo; Barnadas, Agusti; Cortes-Funes, Hernan; Piccart, Martine; Crown, John.
Affiliation
  • Sonnenblick A; Department of Medicine, BrEAST Data Centre, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
  • Francis PA; Peter MacCallum Cancer Centre, Melbourne, Australia; Australia and New Zealand Breast Cancer Trials Group Newcastle, Australia; International Breast Cancer Study Group, Bern, Switzerland.
  • Azim HA; Department of Medicine, BrEAST Data Centre, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
  • de Azambuja E; Department of Medicine, BrEAST Data Centre, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
  • Nordenskjöld B; Swedish Breast Cancer Group, Universitetssjukhuset, Linkoping, Sweden.
  • Gutiérez J; Grupo Oncologico Cooperativo Chileno De Investigacion, Clinica Las Condes, Santiago, Chile.
  • Quinaux E; International Drug Development Institute, Louvain-La-Neuve, Belgium.
  • Mastropasqua MG; University of Milan School of Medicine, and Department of Pathology, European Institute of Oncology, Milan, Italy.
  • Ameye L; Data Management Unit, Institut Jules Bordet, Université Libre de Bruxelles, Belgium.
  • Anderson M; Department of Oncology, Copenhagen University Hospital Rigshospitalet, and Danish Breast Cancer Cooperative Group, Copenhagen, Denmark.
  • Lluch A; Department of Hematology and Medical Oncology, Hospital Clínico Universitario de Valencia/INCLIVA, Universidad de Valencia, Spain(1).
  • Gnant M; Department of Surgery and Comprehensive Cancer Center, Medical University of Vienna, Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria.
  • Goldhirsch A; European Institute of Oncology, Milan, Italy; International Breast Cancer Study Group (IBCSG), Bern, Switzerland.
  • Di Leo A; Sandro Pitigliani' Medical Oncology Department, Hospital of Prato, Istituto Toscano Tumori, Prato, Italy.
  • Barnadas A; Medical Oncology Department, Hospital Santa Creu i Sant Pau, Medicine Department, Universitat Autònoma, Barcelona, Spain(1).
  • Cortes-Funes H; Department of Medical Oncology, University Hospital 12 de Octubre, Madrid, Spain.
  • Piccart M; Department of Medicine, BrEAST Data Centre, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
  • Crown J; St Vincet's University Hospital, Dublin 4, Ireland. Electronic address: john.crown@icorg.ie.
Eur J Cancer ; 51(12): 1481-9, 2015 Aug.
Article in En | MEDLINE | ID: mdl-26074397
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Biomarkers, Tumor / Ki-67 Antigen / Taxoids Type of study: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Female / Humans / Middle aged Language: En Journal: Eur J Cancer Year: 2015 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Biomarkers, Tumor / Ki-67 Antigen / Taxoids Type of study: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Female / Humans / Middle aged Language: En Journal: Eur J Cancer Year: 2015 Document type: Article Affiliation country: Country of publication: